What are the principle third-line options for patients like Christine with metastatic TNBC?
Generally, for metastatic triple negative breast cancer, the first-line therapy is either a taxane such as paclitaxel or docetaxel, or a platinum-based regimen such as gemcitabine plus carboplatin. Usually the secondline is which ever treatment was not utilized as the first-line.
Triple Negative Breast Cancer: Case 1
Christine H is a 54-year-old stay-at-home-mother who works part time as a real estate agent. Medical history is notable for hypertension (well controlled) and surgery for aortic aneurysm in 2011
In September 2013, she presented to her PCP with a right breast lump; mammogram showed a large primary breast mass and two enlarged axillary lymph nodes.
At her follow-up in May 2014, the patient showed progression of the right chest wall metastases, and several new liver lesions were detected.
In December of 2014, she presented with increasing fatigue and chest pain on follow up and her CT scan was consistent with progression of the hepatic metastases, with several new lesions also noted in the lungs; her ECOG performance status (PS) at the time was 1.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
GLP-1 Agonists Poised to Impact Breast Cancer Care
September 25th 2024In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight change in findings from a retrospective trial of patients with breast cancer presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
Read More